A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to allow them to continue making copies of the drugs, The Hill reported June 18.
U.S. District Judge Mark Pittmann ruled June 17 that the FDA had acted appropriately when it determined that supply conditions had improved and that the agency had considered relevant evidence.
In April, Mr. Pittman denied the compounding pharmacies’ bid for an injunction in April, blocking them from making copies of the drugs while litigation was pending.
A lawsuit brought by the Outsourcing Facilities Association alleged that the FDA acted recklessly in removing semaglutide from the shortage list, saying there was evidence the drugs were still in short supply.
Mr. Pittman also rejected an earlier challenge in May brought by the same association over the FDA’s removal of Eli Lilly’s Zepbound and Mounjaro from the shortage list. The OFA then appealed the ruling.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.